Beo Therapeutics AG
Pharmaceuticals - Zürich, Zurich, Switzerland
Beo Therapeutics AG Employees
Beo Therapeutics AG Details
Supplementation with live microbial strains is a novel approach to modulate the synergy between the microbiome and the gastrointestinal system to treat hyperuricemia. A large proportion of the population in the Western world suffers from elevated serum uric acid levels, hyperuricemia. The condition is a causal risk factor for serious diseases such as gout, hypertension, chronic kidney disease and type 2 diabetes. Current standard treatment for hyperuricemia only brings 50% of patients below the recommended treatment target leaving a significant unmet medical need for safe and efficacious treatments. The product will be developed by an innovative combination of a food-supplement development path with pharmaceutical drug development approaches. This accelerates development timelines significantly.The product may be developed for multiple applications as food-supplement, medical food or drug.
Beo Therapeutics AG Technologies
Load Balancers
Apache
CMS
WordPress.org
Fonts
Google Font API
Other
Mobile Friendly